Table S3 from Pooled CRISPR Screening Identifies P-Bodies As Repressors of Cancer Epithelial–Mesenchymal Transition

Liang Fang,Li Zhang,Mengran Wang,Yuhao He,Jiao Yang,Zengjin Huang,Ying Tan,Ke Fang,Jun Li,Zhiyuan Sun,Yanping Li,Yisen Tang,Weizheng Liang,Huanhuan Cui,Qionghua Zhu,Zhe Wu,Yiming Li,Yuhui Hu,Wei Chen

DOI: https://doi.org/10.1158/0008-5472.25338609.v1

2024-01-01

Abstract:Table S3. The list of candidate genes

What problem does this paper attempt to address?

Table S6 from Pooled CRISPR Screening Identifies P-Bodies As Repressors of Cancer Epithelial–Mesenchymal Transition

Liang Fang,Li Zhang,Mengran Wang,Yuhao He,Jia‐Shu Yang,Zengjin Huang,Ying Tan,Ke Fang,Jun Li,Zhiyuan Sun,Yanping Li,Yisen Tang,Weizheng Liang,Huanhuan Cui,Qionghua Zhu,Zhe Wu,Yiming Li,Yuhui Hu,Wei Chen

DOI: https://doi.org/10.1158/0008-5472.25338600.v1

2024-01-01

Abstract:Table S6. The list of differentially expressed proteins upon DDX6 or EDC4 knockout
Pooled CRISPR Screening Identifies P-Bodies as Repressors of Cancer Epithelial-Mesenchymal Transition

Liang Fang,Li Zhang,Mengran Wang,Yuhao He,Jiao Yang,Zengjin Huang,Ying Tan,Ke Fang,Jun Li,Zhiyuan Sun,Yanping Li,Yisen Tang,Weizheng Liang,Huanhuan Cui,Qionghua Zhu,Zhe Wu,Yiming Li,Yuhui Hu,Wei Chen

DOI: https://doi.org/10.1158/0008-5472.can-23-1693

IF: 11.2

2024-01-09

Cancer Research

Abstract:Epithelial-mesenchymal transition (EMT) is a fundamental cellular process frequently hijacked by cancer cells to promote tumor progression, especially metastasis. EMT is orchestrated by a complex molecular network acting at different layers of gene regulation. In addition to transcriptional regulation, post-transcriptional mechanisms may also play a role in EMT. Here, we performed a pooled CRISPR screen analyzing the influence of 1547 RNA binding proteins (RBPs) on cell motility in colon cancer cells and identified multiple core components of P-bodies (PBs) as negative modulators of cancer cell migration. Further experiments demonstrated that PB depletion by silencing DDX6 or EDC4 could activate hallmarks of EMT thereby enhancing cell migration in vitro as well as metastasis formation in vivo. Integrative multi-omics analysis revealed that PBs could repress the translation of the EMT-driver gene HMGA2, which contributed to PB-meditated regulation of EMT. This mechanism is conserved in other cancer types. Furthermore, endoplasmic reticulum (ER) stress was an intrinsic signal that induced PB disassembly and translational derepression of HMGA2. Taken together, this study has identified a function of PBs in regulation of EMT in cancer.

oncology
CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

Meiqin Liu,Shile Gao,Xingjun Xu,Huan Ma,Dongmei Wang,Xueqin Cai,Yang Wang

DOI: https://doi.org/10.22514/ejgo.2024.102

2024-01-01

European Journal of Gynaecological Oncology

Abstract:Cervical cancer is the 4th leading cause of tumor-related deaths among women, primarily due to high-risk Human Papillomavirus (HPV). The role of Collapsin Response Mediator Protein 4 (CRMP4) in cervical cancer remains poorly understood, despite its variable expression across various cancers. This study aimed to investigate the mechanisms by which CRMP4 regulates cervical cancer cell growth as well as Epithelial-Mesenchymal Transition (EMT). Based on transcriptome data from The Cancer Genome Atlas (TCGA), CRMP4 is significantly downregulated in cervical cancer tissues compared to normal tissues. Immunoblot assays revealed lower CRMP4 expression in cervical cancer cell lines. Cell Counting Kit-8 (CCK-8), colony formation and flowcytometry demonstrated that CRMP4 overexpression inhibited cell growth as well as stimulated apoptosis in HeLa as well as SiHa cells. In addition, CRMP4 overexpression increased Epithelial cadherin (E-cadherin) levels and decreased Neural cadherin (N-cadherin) and alpha-Smooth Muscle Actin (alpha-SMA) levels, indicating EMT suppression. CRMP4 overexpression downregulated the Wnt/j3-catenin axis by reducing expressions of j3catenin, Wnt family member 3A (Wnt3a), c-Myc and cyclin D1. In summary, CRMP4 inhibits cervical cancer cell proliferation as well as EMT by mediating the Wnt/j3-catenin axis. CRMP4 may therefore be a potential therapeutic target of cervical cancer.
Table S3 from an in Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Lu Xiao,Wen-Xiao Yang,Yuchen Pei,Hong Luo,Xiao-Guang Li,Yun-Jin Wang,Guo-Liang Zhang,Hong Ling,Zhi-Ming Shao,Xin Hu

DOI: https://doi.org/10.1158/0008-5472.23288827

2023-01-01

Abstract:Table S3. MAGeCK ranking of screen genes in DCIS and CA1a.
Table S2 from An In Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Xun-Xi Lu,Wen-Xiao Yang,Yu-Chen Pei,Hong Luo,Xiao-Guang Li,Yun-Jin Wang,Guo-Liang Zhang,Hong Ling,Zhi-Ming Shao,Xin Hu

DOI: https://doi.org/10.1158/0008-5472.23288830.v1

2023-01-01

Abstract:Table S2. sgRNA sequences of RBP genes in the CRISPR/Cas9 library.
Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191542

2024-01-01

Abstract:Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.
Table S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419825.v1

2023-01-01

Abstract:Supplementary Table S3. Demographics of the included 332 osteosarcomas.
Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395236.v1

2023-01-01

Abstract:Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Table S1 from Epigenetic CRISPR Screens Identify npm1 As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Fēi Li,Wai-Lung Ng,Troy A. Luster,Hai Hu,Vladislav O. Sviderskiy,Catríona M. Dowling,Kate E.R. Hollinshead,Paula Zouitine,Hua Zhang,Qingyuan Huang,Michela Ranieri,Wei Wang,Zhaoyuan Fang,Ting Chen,Jiehui Deng,Kai Zhao,Hon‐Cheong So,Alireza Khodadadi‐Jamayran,Mousheng Xu,Angeliki Karatza,Val Pyon,Shuai Li,Yun Pan,Kristen Labbe,Christina Almonte,John T. Poirier,George Miller,Richard Possemato,Jun Qi,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22425193.v1

2023-01-01

Abstract:Reads count for CRISPR screens
Table S2 from Epigenetic CRISPR Screens Identify Npm1 As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Fei Li,Wai-Lung Ng,Troy A. Luster,Hai Hu,Vladislav O. Sviderskiy,Catríona M. Dowling,Kate E.R. Hollinshead,Paula Zouitine,Hua Zhang,Qingyuan Huang,Michela Ranieri,Wei Wang,Zhaoyuan Fang,Ting Chen,Jiehui Deng,Kai Zhao,Hon-Cheong So,Alireza Khodadadi-Jamayran,Mousheng Xu,Angeliki Karatza,Val Pyon,Shuai Li,Yuanwang Pan,Kristen Labbe,Christina Almonte,John T. Poirier,George Miller,Richard Possemato,Jun Qi,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22425190

2023-01-01

Abstract:Candidate lists for CRISPR screens
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

Julia Joung,Paul C. Kirchgatterer,Ankita Singh,Jang H. Cho,Suchita P. Nety,Rebecca C. Larson,Rhiannon K. Macrae,Rebecca Deasy,Yuen-Yi Tseng,Marcela V. Maus,Feng Zhang

DOI: https://doi.org/10.1038/s41467-022-29205-8

IF: 16.6

2022-03-25

Nature Communications

Abstract:Abstract The cellular processes that govern tumor resistance to immunotherapy remain poorly understood. To gain insight into these processes, here we perform a genome-scale CRISPR activation screen for genes that enable human melanoma cells to evade cytotoxic T cell killing. Overexpression of four top candidate genes ( CD274 (PD-L1), MCL1 , JUNB , and B3GNT2 ) conferred resistance in diverse cancer cell types and mouse xenografts. By investigating the resistance mechanisms, we find that MCL1 and JUNB modulate the mitochondrial apoptosis pathway. JUNB encodes a transcription factor that downregulates FasL and TRAIL receptors, upregulates the MCL1 relative BCL2A1, and activates the NF-κB pathway. B3GNT2 encodes a poly-N-acetyllactosamine synthase that targets >10 ligands and receptors to disrupt interactions between tumor and T cells and reduce T cell activation. Inhibition of candidate genes sensitized tumor models to T cell cytotoxicity. Our results demonstrate that systematic gain-of-function screening can elucidate resistance pathways and identify potential targets for cancer immunotherapy.

multidisciplinary sciences
Supplementary Table 4 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Jianzhong Cao,Yongmei Song,Nan Bi,Jie Shen,Wenyang Liu,Jing Fan,Guogui Sun,Tong Tong,Jie He,Yuankai Shi,Xun Zhang,Ning Lu,Yinghua He,Hongyu Zhang,Kelong Ma,Xiaoying Luo,Lei Lv,Hui Deng,Jing Cheng,Jingde Zhu,Luhua Wang,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22397195

2023-01-01

Abstract:PDF file - 40K, ECOG Performance Status.
Supplementary Table 8 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers

Zhenyu Liu,Yuqiong Hu,Haoling Xie,Kexuan Chen,Lu Wen,Wei Fu,Xin Zhou,Fuchou Tang

DOI: https://doi.org/10.1158/2159-8290.25956939.v1

2024-01-01

Abstract:Supplementary Table 8. Motif enrichment in marker peaks of CIMP-High, CIMP-Low, and CIMP-Negative tumors.
Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758755.v1

2023-01-01

Abstract:Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Gene log2FC in CRISPR screens from B2m-WT cells and B2m-KO cells. ## Common regulators of T cell mediated tumor killing in both B2m-WT and B2m-KO cells
Supplementary Table S4-6 from an in Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Xun-Xi Lu,Wen-Xiao Yang,Yu-Chen Pei,Hong Luo,Xiao-Guang Li,Yun-Jin Wang,Guo-Liang Zhang,Hong Ling,Zhi-Ming Shao,Xin Hu

DOI: https://doi.org/10.1158/0008-5472.23288836.v1

2023-01-01

Abstract:Table S4. Primers used in qPCR assays.Table S5. The association of SNRPC expression with patients’ characteristics.Table S6. Univariate and multivariate analysis of DFS in all patients.
CRB3 Downregulation Confers Breast Cancer Stem Cell Traits Through TAZ/β-catenin

P Li,Y Wang,X Mao,Y Jiang,J Liu,J Li,J Wang,R Wang,J She,J Zhang,J Yang,Y Liu,P Liu

DOI: https://doi.org/10.1038/oncsis.2017.24

2017-01-01

Oncogenesis

Abstract:The cancer stem cell (CSC) theory depicts a special population within the cancer mass that self-renew and sustain the cancer, even if the other cells were eliminated by therapies. How CSCs acquire these unique traits is still unclear. Crumbs homolog 3 (CRB3), a member of the CRB polarity complex, has been reported to act as a tumor suppressor. Here, we detected significantly lower or negative CRB3 expression in human breast cancer tissues. Knockdown of CRB3 generated non-tumorigenic, immortalized breast epithelial cell line MCF 10A with CSC properties. Simultaneously, we found that CRB3 downregulation induced the epithelial–mesenchymal transition and activated TAZ (transcriptional co-activator with PDZ-binding motif) and β-catenin. Significantly, the activation of TAZ and β-catenin sufficed in conferring MCF 10A cells with CSC properties. This study demonstrates that cell polarity proteins may serve as a switch of the differentiated vs multipotent states in breast cancers.
Supplementary Table 1 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Jianzhong Cao,Yongmei Song,Nan Bi,Jie Shen,Wenyang Liu,Jing Fan,Guogui Sun,Tong Tong,Jie He,Yuankai Shi,Xun Zhang,Ning Lu,Yinghua He,Hongyu Zhang,Kelong Ma,Xiaoying Luo,Lei Lv,Hui Deng,Jing Cheng,Jingde Zhu,Luhua Wang,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22397204

2023-01-01

Abstract:PDF file - 53K, The sequences for the four plasmids.
Single-cell Transcriptomic Profiling of Non-Hematopoietic Circulating Cells in Mid-Gestational Mouse Embryos.

Yanyan Li,Yanjuan Chen,Xiaona Zheng,Yun Gao,Yuxuan Zheng,Zongcheng Li,Han He,Fuchou Tang,Bing Liu,Yu Lan

DOI: https://doi.org/10.1016/j.jgg.2021.05.002

2021-01-01

Abstract:The tumor suppressor p53 transactivates the expression of multiple genes to exert its multifaceted functions and ultimately maintains genome stability. Thus, cancer cells develop various mechanisms to diminish p53 expression and bypass the cell cycle checkpoint. In this study, we identified the gene encoding RNA-binding protein cytoplasmic polyadenylation element-binding protein 2 (CPEB2) as a p53 target. In turn, CPEB2 decreases p53 messenger RNA stability and translation to fine-tune p53 level. Specifically, we showed that CPEB2 binds the cytoplasmic polyadenylation elements in the p53 3′-untranslated region, and the RNA recognition motif and zinc finger (ZF) domains of CPEB2 are required for this binding. Furthermore, we found that CPEB2 was upregulated in renal cancer tissues and promotes the renal cancer cell proliferation and migration. The oncogenic effect of CPEB2 is partially dependent on negative feedback regulation of p53. Overall, we identify a novel regulatory feedback loop between p53 and CPEB2 and demonstrate that CPEB2 promotes tumor progression by inactivating p53, suggesting that CPEB2 is a potential therapeutic target in human renal cancer.
Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

Matheus Henrique Dias,Anoek Friskes,Siying Wang,Joao M. Fernandes Neto,Frank van Gemert,Soufiane Mourragui,Chrysa Papagianni,Hendrik J. Kuiken,Sara Mainardi,Daniel Alvarez-Villanueva,Cor Lieftink,Ben Morris,Anna Dekker,Emma van Dijk,Lieke H.S. Wilms,Marcelo S. da Silva,Robin A. Jansen,Antonio Mulero-Sánchez,Elke Malzer,August Vidal,Cristina Santos,Ramón Salazar,Rosangela A.M. Wailemann,Thompson E.P. Torres,Giulia De Conti,Jonne A. Raaijmakers,Petur Snaebjornsson,Shengxian Yuan,Wenxin Qin,John S. Kovach,Hugo A. Armelin,Hein te Riele,Alexander van Oudenaarden,Haojie Jin,Roderick L. Beijersbergen,Alberto Villanueva,Rene H. Medema,Rene Bernards

DOI: https://doi.org/10.1158/2159-8290.26134828

2024-01-01

Abstract:Supplementary table 3: Full list of genes whose knockout attenuated LB-100 toxicity in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change greater or equal to 1 in treated/untreated comparison were criteria for hit selection.

Table S3 from Pooled CRISPR Screening Identifies P-Bodies As Repressors of Cancer Epithelial–Mesenchymal Transition

Table S6 from Pooled CRISPR Screening Identifies P-Bodies As Repressors of Cancer Epithelial–Mesenchymal Transition

Pooled CRISPR Screening Identifies P-Bodies as Repressors of Cancer Epithelial-Mesenchymal Transition

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

Table S3 from an <i>in Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Table S2 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Table S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Table S1 from Epigenetic CRISPR Screens Identify <i>npm1</i> As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Table S2 from Epigenetic CRISPR Screens Identify Npm1 As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

Supplementary Table 4 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Table 8 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers

Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Table S4-6 from an in Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

CRB3 Downregulation Confers Breast Cancer Stem Cell Traits Through TAZ/β-catenin

Supplementary Table 1 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Single-cell Transcriptomic Profiling of Non-Hematopoietic Circulating Cells in Mid-Gestational Mouse Embryos.

Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

Table S3 from Pooled CRISPR Screening Identifies P-Bodies As Repressors of Cancer Epithelial–Mesenchymal Transition

Table S6 from Pooled CRISPR Screening Identifies P-Bodies As Repressors of Cancer Epithelial–Mesenchymal Transition

Pooled CRISPR Screening Identifies P-Bodies as Repressors of Cancer Epithelial-Mesenchymal Transition

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

Table S3 from an &lt;i&gt;in Vivo&lt;/i&gt; CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Table S2 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Table S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Table S1 from Epigenetic CRISPR Screens Identify &lt;i&gt;npm1&lt;/i&gt; As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Table S2 from Epigenetic CRISPR Screens Identify Npm1 As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

Supplementary Table 4 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Table 8 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers

Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Table S4-6 from an in Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

CRB3 Downregulation Confers Breast Cancer Stem Cell Traits Through TAZ/β-catenin

Supplementary Table 1 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Single-cell Transcriptomic Profiling of Non-Hematopoietic Circulating Cells in Mid-Gestational Mouse Embryos.

Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

Table S3 from an <i>in Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Table S1 from Epigenetic CRISPR Screens Identify <i>npm1</i> As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer